Targeting RAD52 overcomes PARP inhibitor resistance in preclinical Brca2-deficient ovarian cancer model.
在临床前 Brca2 缺陷型卵巢癌模型中,靶向 RAD52 可克服 PARP 抑制剂耐药性。
期刊:
影响因子:
doi:10.1101/2025.09.24.678351
Ota Yukihide, Gupta Vijayalaxmi, Fashemi Bisiayo E, Akande Moreniola, Babu Preedia, Thuthika Prasanth, Elizagaray Maia L, Sun Lulu, Sanders Brooke, Kuroki Lindsay M, McCourt Carolyn K, Hagemann Andrea R, Hagemann Ian S, Thaker Premal H, Mutch David G, Powell Matthew A, Hyrc Krzysztof, Verma Priyanka, Krais John, Bitler Benjamin G, Mullen Mary, Khabele Dineo